Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Patrick Aubonnet"'
Autor:
Bin Sun, Nilanjan Sengupta, Anita Rao, Charles Donnelly, Vinit Waichale, Arnab Sinha Roy, Shilpa Ramaswamy, Divya Pathak, Ronald R. Bowsher, Yaron Raiter, Patrick Aubonnet, Abhijit Barve
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials. Immunogenicity of MYL-1501D and reference insulin g
Externí odkaz:
https://doaj.org/article/0bf18c5df35148c4bf95a40d112ace9c
Autor:
Ronald R Bowsher, Divya Pathak, Patrick Aubonnet, Charles Donnelly, Vinit S. Waichale, Bin Sun, Yaron Raiter, Abhijit Barve, Anita Rao, Shilpa G Ramaswamy, Nilanjan Sengupta, Arnab Sinha Roy
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Endocrine Disorders
BMC Endocrine Disorders
Background MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials. Immunogenicity of MYL-1501D and reference insulin glargine w
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To report phase 1 bioequivalence results comparing MYL-1501D, US reference insulin glargine (US IG), and European reference insulin glargine (EU IG). Materials and methods The double-blind, randomized, three-way crossover study compared the phar
Autor:
Bin Sun, Thomas Blevins, Patrick Aubonnet, Yaron Raiter, Sandeep N. Athalye, Abhijit Barve, Rafael Muniz
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL‐1501D and reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey). Materials and met
Autor:
Patrick Aubonnet, Rafael Muniz, Thomas Blevins, Yaron Raiter, Michael Ankersen, Abhijit Barve, Sandeep N. Athalye, Bin Sun
Publikováno v:
Diabetes, Obesity and Metabolism. 21:129-135
Aims To assess the non-inferiority of MYL-1501D, a proposed biosimilar or follow-on biological agent to marketed insulin glargine, to reference insulin glargine (Lantus®; Sanofi-Aventis US LLC, Bridgewater, New Jersey) based on change in glycated he
Autor:
Anna Lochocka, Mario Berli, Cesar Gonzalo Calvo Vargas, Christelle Foucher, Petr Reichert, Axel Schaeffer, Hans-Friedrich Koch, Patrick Aubonnet, Dmitry Belenky
Publikováno v:
Cardiovascular Therapeutics. 33:329-337
SummaryAims Guidelines propose additional therapy to statin to treat elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDLC) in dyslipidemic patients. We evaluated the effects of new fixed-dose combinations (FDC) of fenofibrat
Autor:
Pascale Massin, Tunde Peto, Jean-Claude Ansquer, Patrick Aubonnet, for the MacuFEN Study Investigators
Publikováno v:
Ophthalmic Epidemiology. 21:307-317
Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME.In this double-blind, randomized, placebo-contro
Autor:
Patrick Aubonnet, Jean-Claude Ansquer, Katsuhiro Mihara, Dirk Lehnick, Anneke Winsemius, Stefan Driessen, Hanneke van Assche, Katrin Beckmann, Peter van Amsterdam, Gabi Piskol, Matthias Olbrich
Publikováno v:
The Journal of Clinical Pharmacology. 54:1038-1047
Simvastatin and fenofibrate are frequently co-prescribed at staggered intervals for the treatment of dyslipidemia. Since a drug-drug interaction has been reported when the two drugs are given simultaneously, it is of clinical interest to know whether